feedback

Course Directors

Barbara K. Burton, MD
Barbara K. Burton, MD

Northwestern University Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois

Nicola Longo, MD, PhD
Nicola Longo, MD, PhD

University of Utah
Salt Lake City, Utah

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Jun-14
Expiration Date:2019-Jun-13
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

In this activity, based in part on a live symposium held at the 2018 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meetings, experts in the management of phenylketonuria (PKU) provide guidance for maintaining metabolic control and mitigating neurocognitive impairments in adults with PKU and explore the potential role of established and recently approved adjunctive therapies in relaxing dietary restrictions and improving neurocognitive symptoms in appropriate patient candidates.

Upon completion of this activity, participants should be better able to:

  • Describe the underlying genetics, disease mechanisms, and potential long-term neuropsychiatric and cognitive complications associated with phenylketonuria (PKU)
  • Employ current practice guidelines standards of care when managing individuals with PKU
  • Assess key data on the efficacy, safety, and tolerability of adjunctive pharmacologic therapies for the treatment of PKU
  • Employ adjunctive pharmacologic approaches in individuals with PKU

Target Audience

This activity has been designed to meet the educational needs of medical geneticists, genetic counselors, dieticians, and other clinicians involved in the management of patients with PKU.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 14, 2018 - June 13, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Co-chairs

Barbara K. Burton, MD
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Director, PKU Clinic
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois

Barbara K. Burton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for BioMarin Pharmaceutical Inc.; Horizon Pharma; REGENXBIO Inc.; Reneo Pharmaceuticals, Inc.; Shire; and Viking Therapeutics.
Grant/Research Support from Sangamo Therapeutics, Inc.; Shire; and Ultragenyx Pharmaceutical.
Speakers Bureau participant with Alexion Pharmaceuticals Inc.; Sanofi Genzyme; and Shire.
Advisory Board for Alexion Pharmaceuticals Inc. and Shire.
Other Financial or Material Support from Horizon Pharma for the Data and Safety Monitoring Board; BioMarin Pharmaceutical Inc. for clinical trial steering committee.

Barbara K. Burton, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: treatments for phenylketonuria.

Nicola Longo, MD, PhD
Professor and Chief
Medical Genetics/Pediatrics
University of Utah
Salt Lake City, Utah

Nicola Longo, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Aeglea BioTherapeutics; BioMarin; Censa Pharmaceuticals; Dimension Therapeutics; Genzyme Corporation/sanofi-aventis U.S. LLC; HemoShear Therapeutics, LLC; Horizon Pharma plc; Lumos Pharma; Mitobridge, Inc.; Moderna Therapeutics; Pfizer Inc.; Retrophin, Inc.; and Stealth BioTherapeutics Inc.
Grant/Research Support from Lumos Pharma.
Clinical Trial Support from Aeglea BioTherapeutics; BioMarin; Censa Pharmaceuticals; Genzyme Corporation/sanofi-aventis U.S. LLC; Horizon Pharma plc; Pfizer Inc.; Protalix Ltd.; Retrophin, Inc.; Shire; Stealth BioTherapeutics Inc.; and Ultragenyx Pharmaceutical.
Travel Support from Cello Health and Sigma-Tau Pharmaceuticals, Inc./Alfasigma USA, Inc.

Nicola Longo, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: treatments for phenylketonuria.

CME Reviewer

Staci M. Kallish, DO
University of Pennsylvania School of Medicine
Philadelphia, PA

Staci M. Kallish, DO, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk A. Tacka, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from BioMarin Pharmaceutical Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.